NCT02223819 2023-12-06
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Columbia University
Phase 2 Completed
Clinical Trials
4 trialsNCT02612194 2022-11-03
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT03088930 2022-02-11
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
University of Colorado, Denver
Phase 2 Completed
NCT02510001 2021-07-13
MErCuRIC1
University of Oxford
Phase 1 Completed